Table 2.
Hazard ratios for discontinuation of the three drugs due to specific causes
Etanercept | Tocilizumab | Abatacept | |
---|---|---|---|
(reference) | HR (95 % CI) | HR (95 % CI) | |
All unfavorable causes | 1 | 0.58 (0.13–2.66) | 1.21 (0.33–4.51) |
Inadequate efficacy | 1 | 1.37 (0.12–15.29) | 2.14 (0.21–21.57) |
Adverse events | 1 | 0.28 (0.27–2.82) | 0.77 (0.13–4.42) |
Adjusted by sex, age, concomitant use of methotrexate, disease duration, and clinical disease activity index
HR hazard ratio, CI confidence interval